Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy
2022 · Nature Medicine · 76 citations
https://doi.org/10.1038/s41591-022-01696-4
I
Irene Gañán‐Gómez
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
126
Papers
1.6K
Citations
16
h-index
26
i10-index
Irene Gañán‐Gómez is an academic researcher from The University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Acute Myeloid Leukemia Research & Hematopoietic Stem Cell Transplantation & Myeloproliferative Neoplasms: Diagnosis and Treatment. The author has an h-index of 16, co-authored 108 publications.
ORCID: 0000-0001-8354-3139Papers by this author
worksTargeting DNA2 overcomes metabolic reprogramming in multiple myeloma
2024 · Nature Communications · 9 citations
https://doi.org/10.1038/s41467-024-45350-8
Hematopoietic stem cells with granulo-monocytic differentiation state overcome venetoclax sensitivity in patients with myelodysplastic syndromes
2024 · Nature Communications · 9 citations
https://doi.org/10.1038/s41467-024-46424-3
Accurate identification of locally aneuploid cells by incorporating cytogenetic information in single cell data analysis
2024 · Scientific Reports · 1 citations
https://doi.org/10.1038/s41598-024-75226-2
Supplemental Table 4 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax
2024 · 0 citations
https://doi.org/10.1158/1078-0432.25515448.v1
Supplemental Figure 3 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax
2024 · 0 citations
https://doi.org/10.1158/1078-0432.25515463
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat